Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Hedge Funds

13D Filing: Tang Capital Partners LP and Odonate Therapeutics Inc (ODT)

Published on December 19, 2017 at 2:48 pm by Insider Monkey Staff in Hedge Funds

Odonate Therapeutics Inc (NASDAQ:ODT): Kevin C. Tang’s Tang Capital Partners LP filed an amended 13D.

You can check out Tang Capital Management’s latest holdings and filings here.

Please follow Tang Capital Management (if you aren’t already doing so) to get real-time email alerts whenever we publish an article about Tang Capital Management or update its stock holdings.

Follow Kevin C. Tang's Tang Capital Management

You can access the original SEC filing by clicking here.

Ownership Summary Table

Name Sole Voting Power Shared Voting Power Sole Dispositive Power Shared Dispositive Power Aggregate Amount Owned Power Percent of Class
Tang Capital Partners 0 12,202,338 0 12,202,338 12,202,338 45.4%
Tang Capital Management 0 12,202,338 0 12,202,338 12,202,338 45.4%
Kevin C. Tang 0 12,202,338 0 12,202,338 12,202,338 45.4%

Page 1 of 14 – SEC Filing

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
Under the Securities Exchange Act of 1934
(Amendment No. _)*
Odonate Therapeutics, Inc.
(Name of Issuer)
Common Stock, par value $0.01
(Title of Class of Securities)
676079106
(CUSIP Number)
Kevin C. Tang
 Tang Capital Management, LLC
4747 Executive Drive, Suite 510
San Diego, CA 92121
(858) 200-3830
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
December 6, 2017
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐
Note:  Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
(Continued on following pages)

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 2 of 14 – SEC Filing

CUSIP NO. 676079106
13D
Page 2 of 10
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Tang Capital Partners, LP
2.
Check the Appropriate Box if a Member of a Group
(a) ☐
(b) ý
3.
SEC Use Only
4.
Source of Funds
WC
5.
Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
          ☐
6.
Citizenship or Place of Organization
Delaware
Number of
Shares Beneficially
Owned by
Each Reporting
Person With
7.
Sole Voting Power
0
8.
Shared Voting Power
12,202,338
9.
Sole Dispositive Power
0
10.
Shared Dispositive Power
12,202,338
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
12,202,338
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares          ☐
13.
Percent of Class Represented by Amount in Row (11)
45.4%
14
Type of Reporting Person
PN

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 3 of 14 – SEC Filing

CUSIP NO. 676079106
13D
Page 3 of 10
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Tang Capital Management, LLC
2.
Check the Appropriate Box if a Member of a Group
(a) ☐
(b) ý
3.
SEC Use Only
4.
Source of Funds
WC
5.
Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
          ☐
6.
Citizenship or Place of Organization
Delaware
Number of
Shares Beneficially
Owned by
Each Reporting
Person With
7.
Sole Voting Power
0
8.
Shared Voting Power
12,202,338
9.
Sole Dispositive Power
0
10.
Shared Dispositive Power
12,202,338
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
12,202,338
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares          ☐
13.
Percent of Class Represented by Amount in Row (11)
45.4%
14
Type of Reporting Person
OO

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 4 of 14 – SEC Filing

CUSIP NO. 676079106
13D
Page 4 of 10
1.
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only).
Kevin C. Tang
2.
Check the Appropriate Box if a Member of a Group
(a) ☐
(b) ý
3.
SEC Use Only
4.
Source of Funds
PF, WC, OO
5.
Check If Disclosure of Legal Proceeding Is Required Pursuant to Items 2(d) or 2(e)
          ☐
6.
Citizenship or Place of Organization
United States
Number of
Shares Beneficially
Owned by
Each Reporting
Person With
7.
Sole Voting Power
0
8.
Shared Voting Power
12,202,338
9.
Sole Dispositive Power
0
10.
Shared Dispositive Power
12,202,338
11.
Aggregate Amount Beneficially Owned by Each Reporting Person
12,202,338
12.
Check if the Aggregate Amount in Row (11) Excludes Certain Shares ☐
13.
Percent of Class Represented by Amount in Row (11)
45.4%
14
Type of Reporting Person
IN

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 5 of 14 – SEC Filing

Item 1. Security and Issuer
This Statement on Schedule 13D (the “Statement” or “Schedule 13D”) relates to the common stock, par value $0.01 (the “Common Stock”), of Odonate Therapeutics, Inc., a Delaware corporation (the “Issuer”). The principal executive office of the Issuer is located at 4747 Executive Drive, Suite 510, San Diego, CA 92121.
Item 2. Identity and Background
This Statement is being jointly filed in accordance with the Joint Filing Agreement attached hereto as Exhibit 1 on behalf of the following individuals and entities (each, a “Reporting Person” and collectively, “Reporting Persons”), pursuant to Rule 13d-1(k)(1) promulgated by the Securities and Exchange Commission pursuant to Section 13 of the Securities Exchange Act of 1934, as amended:
Tang Capital Partners, LP
Tang Capital Management, LLC
Kevin C. Tang
Information Regarding Each Reporting Person
Tang Capital Partners, LP
The business address of Tang Capital Partners, LP is:
4747 Executive Drive, Suite 510
San Diego, CA 92121
Tang Capital Partners, LP is a limited partnership engaged in capital management.
Tang Capital Management, LLC
The business address of Tang Capital Management, LLC is:
4747 Executive Drive, Suite 510
San Diego, CA 92121
Tang Capital Management, LLC is a limited liability company that is the general partner of Tang Capital Partners, LP.
Kevin C. Tang
The business address of Kevin C. Tang is:
4747 Executive Drive, Suite 510
San Diego, CA 92121

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 6 of 14 – SEC Filing

Mr. Tang is the manager of Tang Capital Management, LLC. Mr. Tang is also the Chairman of the Board of Directors and Chief Executive Officer of the Issuer.
Information Regarding Legal Proceedings
To the knowledge of the Reporting Persons, no individual or entity identified in this Item 2 has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such party was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
Citizenship
Tang Capital Partners, LP is a Delaware limited partnership. Tang Capital Management, LLC is a Delaware limited liability company. Mr. Tang is a United States citizen.
Item 3. Source and Amount of Funds or Other Consideration
The Reporting Persons have expended an aggregate of approximately $77,000,000 to purchase 12,202,338 shares of the Issuer’s Common Stock. Such purchases were effected in private placements, privately negotiated transactions and the Issuer’s initial public offering, which closed on December 11, 2017. The Common Stock was acquired in the ordinary course of business. Subject to the following paragraph, Tang Capital Partners, LP used its own funds for the purchases, none of which were borrowed or otherwise obtained from any other source.
Tang Capital Partners, LP maintains commingled margin accounts with various financial institutions, which may extend margin credit to Tang Capital Partners, LP as and when required, to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts. The margin accounts may from time to time have debit balances. Since multiple different securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the shares of Common Stock reported herein.
Item 4. Purpose of Transaction
The Reporting Persons are engaged in the investment business. The purpose of the acquisition of the shares of the Issuer’s Common Stock is for investment, and the acquisitions of such stock were made in the ordinary course of the Reporting Persons’ businesses and were not made for the purpose of acquiring control of the Issuer. The Reporting Persons may take such actions in the future with respect to their investment in the Issuer as they deem advisable including, without limitation, purchasing additional shares and/or otherwise changing their intention with respect to the matters referred to in Item 4 of Schedule 13D. Such actions will depend upon various factors including, without limitation, the Issuer’s financial and strategic direction and position, the price performance of the Issuer’s shares, general conditions in the Issuer’s industry, the economy and the securities markets and the availability of other investment opportunities. Mr. Tang is the Chairman of the Board of Directors and Chief Executive Officer of the Issuer. As a result, Mr. Tang regularly has discussions with other members of management, other directors and other stockholders of the Issuer, which discussions from time to time relate to management, governance and board composition, the Issuer’s operations and financial condition or strategic transactions.

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 7 of 14 – SEC Filing

Except as set forth herein, the Reporting Persons do not have any present plan or proposal that would relate to or result in any of the matters set forth in subparagraphs (a) – (j) of Item 4 of Schedule 13D.
Item 5. Interest in Securities of the Issuer.
(a)          Amount beneficially owned and percentage of class:
Tang Capital Partners, LP
12,202,338 shares, representing 45.4% of the class
Tang Capital Management, LLC
12,202,338 shares, representing 45.4% of the class
Kevin C. Tang
12,202,338 shares, representing 45.4% of the class
Tang Capital Partners, LP is the beneficial owner of 12,202,338 shares of the Issuer’s Common Stock. Tang Capital Partners, LP shares voting and dispositive power over such shares of Common Stock with Tang Capital Management, LLC and Kevin C. Tang. Subject to the arrangements described in Item 6 of this Statement, the shares reported as beneficially owned by the Reporting Persons include a total of 154,285 shares of Common Stock that are held of record by Odonate Holdings, LLC (“Holdings”). Holdings has granted a proxy to Tang Capital Partners, LP giving Tang Capital Partners, LP the authority to vote such shares.
Tang Capital Management, LLC, as the general partner of Tang Capital Partners, LP, may be deemed to beneficially own the shares of the Issuer’s Common Stock owned by Tang Capital Partners, LP. Tang Capital Management, LLC shares voting and dispositive power over such shares with Tang Capital Partners, LP and Kevin C. Tang.
Kevin C. Tang, as the manager of Tang Capital Management, LLC, may be deemed to beneficially own the shares of the Issuer’s Common Stock beneficially owned by Tang Capital Partners, LP. Kevin C. Tang shares voting and dispositive power over such shares with Tang Capital Partners, LP and Tang Capital Management, LLC. Mr. Tang disclaims beneficial ownership of all shares reported herein except to the extent of his pecuniary interest therein.
(b)          Voting and disposition powers:
Sole power to vote or direct the vote:
Tang Capital Partners, LP
0 shares
Tang Capital Management, LLC
0 shares
Kevin C. Tang
0 shares

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 8 of 14 – SEC Filing

Shared power to vote or direct the vote:
Tang Capital Partners, LP
12,202,338 shares
Tang Capital Management, LLC
12,202,338 shares
Kevin C. Tang
12,202,338 shares
Sole power to dispose or direct the disposition:
Tang Capital Partners, LP
0 shares
Tang Capital Management, LLC
0 shares
Kevin C. Tang
0 shares
Shared power to dispose or direct the disposition:
Tang Capital Partners, LP
12,202,338 shares
Tang Capital Management, LLC
12,202,338 shares
Kevin C. Tang
12,202,338 shares
(c)          The Reporting Persons have engaged in the following transactions in the Issuer’s Common Stock during the last 60 days:
Entity
Transaction
Trade Date
Shares
Price/Share
Tang Capital Partners, LP
Purchase
December 7, 2017
           1,291,666
          $24.00
(e)          N/A.
Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.
Reference is made to the relationships described in Item 5(a) of this Statement.
The Reporting Persons have entered into a Joint Filing Agreement. See Item 2.
The shares reported as beneficially owned by the Reporting Persons include a total of 154,285 shares of Common Stock that are held of record by Holdings. Holdings has granted a proxy to Tang Capital Partners, LP giving Tang Capital Partners, LP the authority to vote such shares. The irrevocable proxy terminates upon the distribution of the shares subject to the irrevocable proxy to Tang Capital Partners, LP or the written agreement of the parties. The foregoing description is only a summary and is qualified in its entirety by reference to the complete text of the proxy, the form of which is filed as Exhibit 2 hereto.

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 9 of 14 – SEC Filing

Any of the Reporting Persons may from time to time acquire or dispose of Issuer securities. Such acquisitions or dispositions may be made in the open market or in privately negotiated transactions.
Item 7. Material to Be Filed as Exhibits
Exhibit 1:
Joint Filing Agreement
Exhibit 2:
Form of Irrevocable Proxy
*          *          *

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 10 of 14 – SEC Filing

SIGNATURES
After reasonable inquiry and to the best of his or its knowledge and belief, each of the following Reporting Persons certifies that the information set forth in this statement is true, complete and correct.
December 18, 2017
Tang Capital Partners, LP
By:
Tang Capital Management, LLC
By:
/s/ Kevin C. Tang
Kevin C. Tang, Manager
Tang Capital Management, LLC
By:
/s/ Kevin C. Tang
Kevin C. Tang, Manager
/s/ Kevin C. Tang
Kevin C. Tang

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 11 of 14 – SEC Filing

EXHIBIT 1
JOINT FILING AGREEMENT
In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing with all other Reporting Persons (as such term is defined in the Schedule 13D referred to below) on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock, par value $0.01, of Odonate Therapeutics, Inc., and that this Agreement be included as an Exhibit to such joint filing. The Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the undersigned hereby execute this Agreement this 18th day of December, 2017.
Tang Capital Partners, LP
By:
Tang Capital Management, LLC
By:
/s/ Kevin C. Tang
Kevin C. Tang, Manager
Tang Capital Management, LLC
By:
/s/ Kevin C. Tang
Kevin C. Tang, Manager
/s/ Kevin C. Tang
Kevin C. Tang

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 12 of 14 – SEC Filing

EXHIBIT 2
IRREVOCABLE PROXY
This Irrevocable Proxy (this “Proxy”), dated as of December 5, 2017 (the “Effective Date”), is granted by Odonate Holdings, LLC, a Delaware limited liability company (“Holdings”), to: (a) Odonate Therapeutics, Inc., a Delaware corporation (“Odonate”); and (b) Tang Capital Partners, LP, a Delaware limited partnership (“TCP”).
RECITALS:
WHEREAS, as of the Effective Date, Holdings is the record holder of a total of 3,085,687 shares of Odonate’s Common Stock, par value $0.01 per share (the “Common Stock”), of which: (a) 154,285 shares (the “TCP Shares”) are currently being held for the benefit of TCP; and (b) 2,931,402 shares (the “Incentive Shares”) are currently being held for the potential satisfaction of equity awards granted by Odonate Management Holdings, LLC (“Management Holdings”);
WHEREAS, Holdings wishes to grant a proxy to Odonate (with respect to voting of the Incentive Shares) and TCP (with respect to the voting of the TCP Shares), in each case in accordance with, and subject to, the terms set forth herein.
NOW, THEREFORE, in consideration of the foregoing, Holdings hereby agrees as follows:
1.          Grant of Proxies.
(a)          Holdings hereby appoints Odonate as Holdings’ attorney and proxy, solely to the extent of Holdings’ rights in the Incentive Shares, to vote the Incentive Shares on all matters submitted to Odonate’s stockholders. In voting the Incentive Shares pursuant to this proxy, Odonate shall be required to vote such shares in the same proportion as the votes cast by other holders of Odonate’s Common Stock (as determined by the inspector of elections at any given election). Except as set forth below, Holdings intends this proxy to be irrevocable and coupled with an interest.
(b)           Holdings hereby appoints TCP or its assigns as Holdings’ attorney and proxy, solely to the extent of the undersigned’s rights in the TCP Shares, to vote the TCP Shares in TCP’s sole and absolute discretion. Except as set forth below, Holdings intends this proxy to be irrevocable and coupled with an interest.
2.          Term and Termination. The proxies granted herein shall expire in whole or in part immediately and without further action on the part of Holdings, Odonate or TCP (collectively, the “Parties”) as follows: (a) with respect to that portion of the Incentive Shares or the TCP Shares that are distributed to Management Holdings or TCP, as applicable; and (b) upon written agreement of the Parties (as applicable, on a share-by-share basis, the “Expiration Date”).

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 13 of 14 – SEC Filing

3.          Miscellaneous.
(a)          Whenever possible, each provision of this Proxy will be interpreted in such manner as to be effective and valid under applicable law, provided that if any provision of this Proxy is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or portion of any provision in such jurisdiction, and this Proxy will be reformed, construed and enforced in such jurisdiction as if such invalid, illegal or unenforceable provision or portion of any provision had never been contained herein.
(b)          This Proxy shall be governed and construed in accordance with the laws of the State of Delaware, without giving effect to the principles of conflicts of law thereof.
(c)          Holdings hereby revokes any proxies previously granted and represents that none of such previously-granted proxies are irrevocable.
(d)          Notwithstanding anything contained herein to the contrary, this proxy shall automatically terminate upon the Expiration Date.
*   *   *   *   *

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Page 14 of 14 – SEC Filing

IN WITNESS WHEREOF, the undersigned have executed this Proxy on the date set forth above.
ODONATE HOLDINGS, LLC
By:
/s/ John G. Lemkey
Name:
John G. Lemkey
Title:
Chief Financial Officer
ODONATE THERAPEUTICS, INC.
By:
/s/ John G. Lemkey
Name:
John G. Lemkey
Title:
Chief Financial Officer
TANG CAPITAL PARTNERS, LP
By:
/s/ Kevin C. Tang
Name:
Kevin C. Tang
Title:
Manager
Tang Capital Management, LLC, General Partner

Follow Odonate Therapeutics Inc. (NASDAQ:ODT)

Related Insider Monkey Articles
13D Filing: RA Capital Management and Dicerna Pharmaceuticals Inc (DRNA)13D Filing: GAMCO Investors and Ingles Markets Inc (IMKTA)
13D Filing: GoldenTree Asset Management and Eagle Bulk Shipping Inc. (EGLE)13D Filing: Elliott Associates, L.P. and Akamai Technologies Inc (AKAM)
13D Filing: Basswood Capital and Regional Management Corp. (RM)13D Filing: Fir Tree and Sandridge Energy Inc (SD)